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Introduction
IL-12 is an important inflammatory
mediator in cell-mediated immunity
(1). IL-12 is a 70-kDa heterodimeric
secreted protein consisting of two
disulfide-linked subunits designated
p40 and p35. It is produced mainly by
antigen-presenting cells upon activa-
tion through Toll-like receptors and by
interactions with T cells. Engagement
of the IL-12 receptor complex on T
cells has been shown to be critical in
Th1-mediated immunity and Th1
polarization (2, 3). Furthermore, there
is overwhelming evidence that IL-12
plays an essential role in the patho-
genesis of multiple sclerosis and its
animal model, experimental autoim-
mune encephalomyelitis (EAE) (1, 4,
5). Both multiple sclerosis and EAE are
considered to be Th1-mediated
autoimmune diseases in which neu-
roantigen-reactive lymphocytes infil-
trate the CNS, mediate the develop-
ment of inflammatory lesions, and in
some models, trigger the demyelina-
tion of axons leading to progressive
paralysis (6). In humans, elevated 
IL-12 levels have been reported in pro-
gressive multiple sclerosis (7, 8), and
increased frequencies of IL-12–secret-
ing monocytes appear to correlate
with active brain lesions detected by
magnetic resonance imaging (9). Final-
ly, IL-12 has been functionally impli-
cated in the development of EAE by
the observations that αIL-12 (αp70)
blocks disease development in mice
and IL-12 p40–/– mice are resistant to
EAE induction.
It has recently been reported that the
IL-12 p40 subunit is also a component
of other molecules, including p40
homodimers and IL-23 (10). Therefore,
studies that have implicated IL-12
based solely on alterations in p40 func-
tion or expression may be misleading
due to the use of the p40 subunit by
cytokines other than IL-12. In fact, dis-
cordant immune responses have been
observed between p35–/– and p40–/–
mice, bringing into question the essen-
tiality of IL-12 in these particular mod-
els (11–14). In this report, the reevalu-
ation of IL-12 subunits in EAE has
revealed that p35–/– mice are suscepti-
ble, but p40–/– mice are resistant to
EAE. Therefore, while p40 is absolute-
ly critical for the development of EAE,
IL-12 is completely dispensable.
Methods
Peptide, antibodies, and ELISA. MOG35–55
peptide (MEVGWYRSPFSRVVHLY-
RNGK) was obtained from Research
Genetics (Huntsville, Alabama, USA).
ELISAs for IL-2, IL-4, IFN-γ, and IL-12
p70 were performed with kits pur-
chased from Pharmingen (San Diego,
California, USA), following the manu-
facturer’s guidelines. All antibodies for
flow cytometry (CD45, CD11b, CD8α,
CD4, and GR-1) were preconjugated
with either phycoerythrin, FITC,
PerCP, or biotin, and were purchased
from Pharmingen.
Induction of EAE. Female C57BL/6
mice were obtained from NCI Labora-
tories (Frederick, Maryland, USA).
Homozygous IL-12 p35–/– and IL-12
p40–/– C57BL/6 mice were originally
purchased from The Jackson Labora-
tory (Bar Harbor, Maine, USA) and
were bred in-house under pathogen-
free conditions.
Female C57BL/6, IL-12 p40–/–, and
p35–/– mice 5–8 weeks old were immu-
nized subcutaneously with 200 µg of
MOG35–55 peptide emulsified in CFA
supplemented with 5 mg/ml of
Mycobacterium tuberculosis (H37RA;
Difco Laboratories, Detroit, Michigan,
USA). The mice received intraperitoneal
injections with 250 ng pertussis toxin
(Sigma-Aldrich, St. Louis, Missouri,
USA) at the time of immunization and
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(EAE); keyhole limpet hemocyanin (KLH);
lymph node (LN); wild-type (WT).
48 hours later. After 7 days, the mice
received an identical booster immu-
nization with MOG/CFA without per-
tussis toxin. Clinical disease usually
commences between day 16 and day 20
after immunization.
Clinical evaluation. The mice were
scored four times per week as follows:
0, no detectable signs of EAE; 0.5, limp
distal tail; 1, complete limp tail; 1.5,
limp tail and hind limb weakness; 2,
unilateral partial hind limb paralysis;
2.5, bilateral partial hind limb paraly-
sis; 3, complete bilateral hind limb
paralysis; 3.5, complete hind limb
paralysis and unilateral forelimb paral-
ysis; 4, total paralysis of both forelimbs
and hind limbs; 5, death. Mice scoring
greater than 4 but less than 5 were
euthanized.
Flow cytometry. Mice were euthanized
with CO2, and spinal cords were
removed by flushing the spinal column
with sterile HBSS. The brain was dis-
sected to isolate the brain stem. Both
tissues were homogenized and strained
through a 100-µm nylon filter (Fisher
Scientific Co., Pittsburgh, Pennsylva-
nia, USA). After centrifugation, the cell
suspension was resuspended in 37%
isotonic Percoll and underlaid with
70% isotonic Percoll. The gradient was
centrifuged at 600 g for 25 minutes at
room temperature. The interphase
cells were collected and washed exten-
sively prior to staining. For flow cytom-
etry, the cells were stained with primary
antibodies for 30 minutes at 4°C,
washed, and incubated with strepta-
vidin-conjugated allo-phycocyanin or
PerCP (Pharmingen) for 15 minutes.
The cells were washed and analyzed
with a FACSCalibur flow cytometer
using CellQuest software (Becton,
Dickinson and Co., San Jose, Califor-
nia, USA). Postacquisition analysis was
performed using WinMDI 2.8 software
(Scripps Research Institute, La Jolla,
California, USA).
Histology. Mice were euthanized with
CO2. The spinal column was removed
and fixed in 10% buffered formalin.
The spinal cord was dissected and
embedded in paraffin prior to stain-
ing with hematoxylin and eosin to
assess infiltration.
Recall responses and in vitro IL-12 pro-
duction. Mice were primed by flank
injections of 100 µg keyhole limpet
hemocyanin/CFA (KLH/CFA) (Cal-
biochem-Novabiochem Corp., La Jolla,
California, USA). After 5 days, the axil-
lary and inguinal lymph nodes (LNs)
were removed and homogenized. LN
cells (5 × 105) were placed as triplicates
in a 96-well plate and pulsed with dif-
ferent amounts of KLH or irrelevant
protein (grade VI chicken ovalbumin;
Sigma-Aldrich) as a control. After 48
hours, cells were pulsed with
[3H]thymidine (NEN Life Science
Products Inc., Boston, Massachusetts,
USA) and incubated for an additional
15 hours before cells were harvested.
Thymidine incorporation was assessed
using a FilterMate harvester and a
TopCount NXT microplate scintilla-
tion and luminescence counter (both
from Packard BioScience Co., Meri-
den, Connecticut, USA). Sister cul-
tures were harvested 48 hours later for
cytokine analysis, and culture super-
natants were analyzed by ELISA for
IFN-γ, IL-2, and IL-4 (Pharmingen).
To measure IL-12 production in
vitro, spleens were removed and
homogenized. Red blood cells were
lysed, and 5 × 105 splenocytes were
stimulated with 1 µg/ml LPS (Sigma-
Aldrich) and 10 ng/ml IFN-γ (Pepro-
Tech Inc., Rocky Hill, New Jersey, USA)
in 96-well plates. Culture supernatants
were harvested and analyzed for IL-12
p70 by ELISA (Pharmingen).
Real-time PCR. RNA was extracted
from spinal cords of mice with EAE as
described (15). Briefly, the spinal col-
umn was flushed with ice-cold HBSS
and the cords were homogenized in
Trizol reagent (Invitrogen Corp., San
Diego, California, USA). RNA was
extracted following manufacturer
instructions. The samples were treated
with DNase using DNA-free (Ambion
Inc., Austin, Texas, USA), and 5 µg of
RNA was transcribed into cDNA using
oligo(dT) primers and the SuperScript
II MMLV-RT kit (Invitrogen Corp.).
Twelve nanograms per well of cDNA
was transferred into iCycler 96-well
plates (Bio-Rad Laboratories Inc., Her-
cules, California, USA), and SYBR
Green PCR master mix (Applied
Biosystems, Foster City, California,
USA) was added following the manu-
facturer’s instructions. PCR was per-
formed on an iCycler with an optical
unit (Bio-Rad Laboratories Inc.). The
PCR conditions were: 5 seconds of
denaturing at 95°C followed by 40
cycles of 15 seconds at 95°C, 45 
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Figure 1
IL-12 is not required for clinical disease development. EAE was induced by active immuniza-
tion of WT (diamonds), p35-/- (squares) and p40-/- (circles) mice with MOG35–55 emulsified
in CFA. Clinical disease was monitored and statistical significance assessed using an unpaired
Student’s t test. Each data point represents the mean of n animals in one experiment that
was repeated at least two more times. #P < 0.05, *P < 0.01, comparison to WT mice.
Table1
EAE in experimental mice
Genotype Incidence Mean day of Mean maximal
disease onsetA clinical scoreA
WT 6/6 19.8 2.0 ± 0.2
P35–/– 5/5 19.4 3.4 ± 0.3
P40–/– 0/6 ND ND
Data shows a disease report of the experiment shown in Figure 1 above. ND, no disease. AOf diseased mice.
seconds at 63°C, and 15 seconds at
72°C. Amplicon accumulation was
measured during the extension phase.
















efficiency for each primer was
90–100%, based on the slope generated
by standard curves using specific
amplicons. A standard curve was gen-
erated for each 96-well plate using a
plasmid containing the β-actin ampli-
con. Data were analyzed using the iCy-
cler analysis software, version 2.3.
Results
Development of EAE in IL-12–deficient
mice. In the course of studying the role
of IL-12 in the development of EAE,
discordant disease development was
noted when comparing p35–/– with
p40–/– mice. In order to comprehensive-
ly evaluate the susceptibility of IL-12
p40–/– and p35–/– mice to EAE, mice were
immunized with MOG35–55 peptide
emulsified in CFA, and the course of
the clinical disease was measured. As
expected (16), p40–/– mice did not show
any clinical disease (Figure 1 and Table
1). In contrast to p40–/– mice, p35–/–
mice were highly susceptible to EAE,
and when compared with wild-type
(WT) mice, the p35–/– mice showed clin-
ical symptoms that were significantly
more severe. Histological analysis of the
inflamed CNS tissue revealed that
p35–/– mice develop severe inflamma-
tion (Figure 2c). Cytofluorimetric
analysis of the infiltrates indicated that
p35–/– mice have higher numbers of
infiltrating lymphocytes (CD45hi/
CD11b–) than do WT mice (39% vs.
28%). Furthermore, within the infiltrat-
ing lymphocyte population, p35–/– mice
showed an increased percentage of CD8
T cells compared with the WT (34% 
vs. 20%) (Figure 3). There were other-
wise no overt differences in the cellular
composition of the infiltrates. The dis-
ease susceptibility and histological
analysis of the p35–/– mice and disease
resistance of the p40–/– mice establish
that a p40-containing cytokine distinct
from IL-12 is essential for the develop-
ment of this disease.
Both p35–/– mice and p40–/– mice display a
marked failure to induce antigen-driven
IFN-γ secretion. Based on antibody
blocking studies and studies in p40–/–
mice, IL-12 has been implicated in the
polarization of Th cells into encephali-
togenic Th1 cells. Given the discordant
behavior of the p35–/– and p40–/– mice
with regard to the development of EAE,
studies were extended to evaluate
whether each of these mice could gen-
erate Th1-type responses. First, the
inability of LPS/IFN-γ–stimulated
splenocytes from both the p35–/– and
p40–/– mice to produce IL-12 p70 pro-
tein was established (Figure 4a). In
order to confirm the role of IL-12 in
Th1 skewing, primed T cells from
p40–/–, p35–/–, and WT mice were rechal-
lenged in vitro and IFN-γ production
was measured. Although all three
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Figure 2
CNS inflammation in IL-12 p35–/– mice. Animals were sacrificed at day 28 after immunization,
and spinal cord inflammation was assessed by hematoxylin and eosin staining. Magnification:
×100. (a) Nonimmunized WT control. (b) Immunized WT mouse. (c) Immunized IL-12 p35–/–
mouse. (d) Immunized IL-12 p40–/– mouse.
Figure 3
Cellular makeup of infiltrates. Animals were sacrificed at day 24 after immunization, and
spinal cord inflammation was assessed by flow cytometry. Infiltrates were stained with anti-
bodies against CD45, CD11b, CD4, CD8, and GR-1 as described in Methods. Gate statis-
tics are expressed as percentages as follows (WT:p35–/–): R1 (lymphocyte gate
CD45hi/CD11b–) = 28%:39%; R2 (macrophage/granulocyte gate CD45hi/CD11b+) = 8%:10%;
R3 (microglia gate CD45lo/CD11b+) = 30%:25%.
groups were virtually indistinguishable
with regard to the levels of antigen-
induced proliferation (Figure 4b) and
IL-2 secretion (Figure 4c), both p35–/–
and p40–/– animals showed severe
defects in stimulating IFN-γ secretion
(Figure 4d) compared with WT. Levels
of IL-4 were at the limit of detectability
and were similar among all groups (not
shown). The data confirm that both
subunits of IL-12 are required to gener-
ate bioactive IL-12 and to polarize 
IFN-γ–secreting cells.
The inflamed CNS tissue in p35–/– mice
displays a Th2 bias. To assess the
cytokine expression profile of CNS-
infiltrating cells, spinal cords were
harvested from WT, p35–/–, and p40–/–
mice 24 days after immunization, and
cytokine expression within the
inflamed tissue was analyzed by real-
time PCR. Cytokine mRNA expres-
sion levels were not included from
p40–/– mice due to lack of infiltrating
cells. Overall, when comparing p35–/–
mice with WT mice, levels of TNF-α
were significantly reduced, whereas
IL-4 and IL-10 levels were increased
(Figure 5). IFN-γ and LT-α levels were
both consistently reduced in p35–/–
mice, yet not to the same extent as
TNF-α. The data indicate that the
inflamed CNS tissue of p35–/– mice
displays a Th2 bias.
Discussion
The role of IL-12 in EAE has been
addressed based on the differential
susceptibility of p35–/– mice and p40–/–
mice to the development of EAE. The
data show that the p35–/– animals
develop severe EAE when immunized
with MOG peptide, whereas p40–/–
mice are resistant to disease develop-
ment. Thus, IL-12 p70 cannot be
required for the development of EAE.
In contrast, IL-12 p70 was shown to
be required for Th1 differentiation by
the fact that neither the p35–/– nor the
p40–/– mice could support the differ-
entiation of IFN-γ–producing T cells
during a primary immune response.
The notion that EAE is an IL-12–
dependent disease was based on stud-
ies using neutralizing αIL-12 anti-
bodies and studies in p40–/– mice
(reviewed in refs. 1, 3, and 17). Studies
have since shown that antibodies
raised against IL-12 p70 and used to
inhibit IL-12 block the common p40
subunit used not only by IL-12 but
also by IL-23 (10) and p40 homod-
imers. Hence, neutralizing of disease
by these antibodies does not allow
one to discriminate between IL-12
and other molecules using p40 in
mediating disease development. Prior
to the realization that the p40 sub-
unit was a common cytokine subunit,
the role of IL-12 in disease develop-
ment was also implicated by the find-
ing that IL-12 p40–/– mice were com-
pletely resistant to EAE (5). The data
presented herein confirm that the
p40 subunit is critical for disease
development and T cell encephalito-
genicity; however, this cannot be
attributed to IL-12 p70, since p35–/–
mice were susceptible to EAE.
To investigate whether the lack of
p35 leads to a change in the inflam-
matory makeup compared with the
WT, we used flow cytometry to quan-
tify the number of infiltrating lym-
phocytes, macrophages, and granulo-
cytes. In contrast to mice lacking IFN-γ
that also develop severe EAE and dis-
play an increased number of GR-1+
neutrophils within the inflamed tissue
(18), we cannot detect a major change
in the infiltrating CD11b+ popula-
tions. However, there is an increased
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Figure 4
p35–/– and p40–/– mice fail to generate Th1 immune responses. (a) Splenocytes from p35–/–,
p40–/–, and WT mice were unstimulated (black bars) or were stimulated for 48 hours with
IFN-γ and LPS (white bars). IL-12 p70 secretion was measured by ELISA. (b–d) p35–/–, p40–/–,
and WT mice were immunized subcutaneously with KLH in CFA. After 5 days, recall respons-
es of LN cells to either KLH (gray bars) or irrelevant ovalbumin (black bars) were measured
by (b) [H]thymidine-uptake, (c) IL-2 ELISA, and (d) IFN-γ ELISA. Shown is a representative
of at least two individual experiments.
Figure 5
Expression profile of inflamed spinal cords. RNA was isolated as described from inflamed
spinal cords 24 days after immunization. Real-time RT-PCR analysis was performed by meas-
uring amplicon accumulation using SYBR Green dye (white bars, WT; black bars, p35–/–).
Data are expressed as arbitrary units based on the standard curve of triplicate wells ± SD.
Values shown are representative of at least three individual experiments. Levels of β-actin
mRNA were similar in both samples; other mRNA species levels were normalized to β-actin.
number of infiltrating lymphocytes —
mostly CD8+ T cells in the p35–/– CNS
— compared with the WT.
We further investigated the expres-
sion profile of the inflamed CNS with
regard to Th1 and Th2 cytokines.
Overall, in p35–/– mice, we see an
increase in Th2 cytokines such as IL-4
and IL-10 and a decrease in TNF-α. In
contrast to the in vitro recall respons-
es, where we could not detect IFN-γ
produced by p35–/– LN cells, the p35–/–
CNS shows abundant IFN-γ message
during EAE. This is in contrast to sec-
ondary lymphoid tissues (spleen),
where we did not detect significant
levels of IFN-γ. The CNS environment
in p35–/– mice displays an increase in
Th2 cytokines, indicating that a Th1
profile is not a requirement for
encephalitogenicity. This is in accor-
dance with the observation that Th2
cell lines generated from myelin basic
protein–TcR transgenic mice can cause
EAE in immunodeficient hosts (19).
The studies presented suggest that
an activity associated with p40 other
than IL-12 activity is required for the
development of EAE. There are at least
two cytokine complexes described that
use p40 in addition to IL-12. First,
there are p40 homodimers that can be
found in mice during an immune
response (20, 21). However, p40
homodimers have been shown to act
as IL-12 receptor antagonists and are
considered to have anti-inflammatory
properties (22, 23). Thus, p40 homod-
imers are not likely to be responsible
for the generation of encephalitogenic
T cells in p35–/– mice. Nonetheless, one
cannot exclude the possibility that p40
or p40 homodimers have agonistic
activity, as suggested by Holscher et al.
(24). Another potential explanation is
that the newly discovered IL-23
(p40/p19) is responsible for the devel-
opment of EAE in p35–/– mice. Indeed,
transgenic mice that overexpress the
p19 subunit ubiquitously display
severe inflammation and multiorgan
failure, indicating that IL-23 has
strong proinflammatory properties
(25). Similar to p35, p19 expression
does not appear to be tightly regulated
and is expressed in various tissues and
by many different cell types independ-
ent of activation and inflammation
(10, 25). Expression of p40, however, is
tightly regulated (3). Similar to IL-12,
IL-23 is produced by activated
macrophages and dendritic cells. IL-23
also binds the IL-12β1 receptor sub-
unit, but not IL-12Rβ2 (10). A dedicat-
ed IL-23 receptor that pairs with 
IL-12Rβ1 has just been identified (26).
Nonetheless, IL-12 p70 is clearly not
involved in the development of this
disease, an important new finding that
challenges contemporary dogma.
Over the years, studies using geneti-
cally deficient mice have convincingly
shown that cytokines such as IFN-γ and
TNF-α are dispensable for the develop-
ment of EAE (27, 28). Yet both multiple
sclerosis and EAE are considered Th1-
mediated diseases, mostly due to the
fact that IL-12 was considered neces-
sary for disease development and
pathology. We now can dismiss IL-12 as
a critical mediator of this disease, and
so the basic conceptual underpinnings
of EAE as a Th1 inflammatory disorder
need to be reconsidered.
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